Research Square
March 31, 2026
Marcus W. Meinhardt, Ivan Skorodumov, Florian Walter et al.
A compound derived from ibogaine, oxa-noribogaine, reduces alcohol consumption in rats by strengthening learning from negative drinking outcomes. It produces sustained decreases in alcohol intake and relapse-like drinking, matching or exceeding ibogaine's efficacy without detectable motor or cardiac side effects. These effects involve transient changes in prefrontal brain activity, lasting alterations in glutamatergic signaling after aversion-related learning, and normalization of neurotrophic signaling in cortico-striatal circuits. The results generalize across multiple models, genetically diverse animals, and independent study sites, identifying oxa-noribogaine as a promising treatment candidate for alcohol use disorder.
bioRxiv (Cold Spring Harbor Laboratory)
March 24, 2026
Kenneth Shinozuka, Mattia Rosso, Anna Chaiken et al.
1 citation
A single dose of the atypical psychedelic ibogaine can be highly effective at treating PTSD in veterans up to twelve months later, according to an observational study of 30 veterans. Using a novel EEG analysis method, researchers found that ibogaine shifted high-beta (24 and 25 Hz) brain networks from frontal areas toward posterior regions, an effect seen both three to four days and one month after treatment. This posterior shift correlated with improvements in PTSD symptoms and was replicated in an independent dataset on ibogaine for opioid use disorder. Neural modeling suggested the shift reflects increased corticocortical, not corticothalamic, connectivity. The reconfiguration of high-beta networks may be a robust biomarker for ibogaine's therapeutic effects.
Journal of Psychedelic Studies
March 9, 2026
Genís Ona, Sidsel Marie
Ibogaine, a psychedelic alkaloid, has a history before its 1960s anti-addictive discovery that involves colonial appropriation, early pharmaceutical research, and commodification. During French colonial rule, ibogaine-containing plants from the Congo Basin were classified and appropriated. In 1900, ibogaine was isolated from Tabernanthe iboga, leading to early French scientific research on its effects. Throughout the 20th century, ibogaine was commercialized in several pharmaceutical products, including Dragées Nyrdahl, Grains des Anémiques, Syséros, Viris Lucet, Ibobiose, and Iperton. Evidence shows ibogaine was used in Mexico in 1913 for substance use disorder, challenging the dominant account of its anti-addictive discovery. Indigenous medicinal knowledge from the Congo Basin critically shaped subsequent scientific understanding.
Addiction Biology
March 1, 2026
Isis Koutrouli, Vojtěch Brejtr, Marek Schwendt et al.
Psilocybin and ibogaine, given in a dose-escalation protocol, facilitated extinction learning in male rats that had self-administered cocaine. Psilocybin reduced active lever pressing one day after the second dose, with a nonsignificant reduction after the first dose; ibogaine significantly reduced pressing even after the first administration. Neither drug significantly altered cue-induced reinstatement of drug-seeking, though psilocybin showed a trend toward attenuation. The treatments had no side effects on general locomotor activity or anxiety-like behavior in the open field test. These results suggest psilocybin and ibogaine may support extinction learning and possibly protect against relapse, warranting further research into their antiaddictive potential.
Planta Medica
March 1, 2026
K Knížková, D Lovás, R Batelková et al.
The plant Tabernanthe iboga contains ibogaine, an alkaloid that helps treat addiction by easing withdrawal and reducing cravings. Because authentic T. iboga from Africa is scarce, other plants with potentially toxic alkaloids are sometimes substituted, leading to fatal overdoses. This study developed an HPLC-MS method to analyze 11 iboga alkaloids and their derivatives, testing different extraction solvents; ethyl acetate with ammonium hydroxide worked best. Real samples from ibogaine clinics were analyzed to assess quality control and risks. The method aims to distinguish T. iboga from plants that might be used to falsify it, improving safety.